-- TEPEZZA significantly improved the clinical course of Thyroid Eye Disease (TED) in all patient subgroups, including those with more severe disease at baseline -- -- For patients in the follow-up ...

TED is a serious, progressive and vision-threatening rare autoimmune disease.1 TED often occurs in people living with hyperthyroidism or Graves’ disease; however, it is a distinct disease that is ...

Horizon Therapeutics HZNP announced positive top-line results from its ongoing phase III study on Tepezza for the treatment of Thyroid Eye Disease (TED) in Japanese patients with higher levels of ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Patients who received Tepezza to treat thyroid eye disease showed improved extraocular muscle size ...

THOUSAND OAKS, Calif., April 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that provide important insights into the mechanisms of TEPEZZA™ (teprotumumab-trbw), illustrating its ...

-- Additional data from OPTIC 48-week follow-up study and OPTIC-X extension trial, including findings showing that the majority of TEPEZZA patients who were diplopia (double vision) responders in ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...

Amgen announced positive topline results from a phase 3 trial of Tepezza (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with ...

-- Oral presentation will highlight results from the OPTIC 48-week off-treatment follow-up period, including long-term proptosis (eye bulging) response and diplopia (double vision) improvement -- -- ...